Chengdu Easton Biopharmaceuticals Co Ltd Total Assets
Chengdu Easton Biopharmaceuticals Co Ltd total assets. Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) holds total assets worth CN¥3.82 Billion CNY (≈ $559.60 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 688513 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
Total assets of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. See Chengdu Easton Biopharmaceuticals Co Ltd share price for real-time trading data and today's change.
Chengdu Easton Biopharmaceuticals Co Ltd - Asset Composition Analysis
Chengdu Easton Biopharmaceuticals Co Ltd Total Assets Breakdown (December 2025)
Chengdu Easton Biopharmaceuticals Co Ltd total assets breakdown as of December 2025. Chengdu Easton Biopharmaceuticals Co Ltd's total assets of CN¥3.82 Billion consist of 56.1% current assets and 43.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 22.5% |
| Accounts Receivable | CN¥181.29 Million | 4.8% |
| Inventory | CN¥228.71 Million | 6.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥301.22 Million | 7.9% |
| Goodwill | CN¥23.10 Million | 0.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688513 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Easton Biopharmaceuticals Co Ltd's current assets represent 56.1% of total assets in 2025, an increase from 34.8% in 2013.
- Cash Position: Cash and equivalents constituted 22.5% of total assets in 2025, up from 11.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 5.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 7.9% of total assets.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Chengdu Easton Biopharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
Chengdu Easton Biopharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.25 | 3.46 | 4.20 |
| Quick Ratio | 2.88 | 3.09 | 3.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.50 Billion | CN¥1.43 Billion | CN¥1.41 Billion |
Chengdu Easton Biopharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chengdu Easton Biopharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | CN¥3.80 Billion |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Easton Biopharmaceuticals Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chengdu Easton Biopharmaceuticals Co Ltd's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below shows the annual total assets of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.80 Billion ≈ $555.75 Million |
+11.70% |
| 2024-12-31 | CN¥3.40 Billion ≈ $497.55 Million |
+1.59% |
| 2023-12-31 | CN¥3.35 Billion ≈ $489.74 Million |
+10.91% |
| 2022-12-31 | CN¥3.02 Billion ≈ $441.56 Million |
+8.73% |
| 2021-12-31 | CN¥2.78 Billion ≈ $406.11 Million |
+9.66% |
| 2020-12-31 | CN¥2.53 Billion ≈ $370.34 Million |
+156.40% |
| 2019-12-31 | CN¥987.08 Million ≈ $144.44 Million |
+25.00% |
| 2018-12-31 | CN¥789.69 Million ≈ $115.56 Million |
+33.40% |
| 2017-12-31 | CN¥591.98 Million ≈ $86.63 Million |
+13.79% |
| 2016-12-31 | CN¥520.22 Million ≈ $76.12 Million |
+66.94% |
| 2015-12-31 | CN¥311.63 Million ≈ $45.60 Million |
+10.08% |
| 2014-12-31 | CN¥283.10 Million ≈ $41.43 Million |
+11.08% |
| 2013-12-31 | CN¥254.86 Million ≈ $37.29 Million |
-- |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. I… Read more